Neurocrine Q4 INGREZZA sales $399M; guides FY23 INGREZZA $1.67-1.77B

NEUROCRINE BIOSCIENCES INC

2022-FY EPS reported $1.56 revenue$1,488,700,000

Q4 2022 INGREZZA net product sales $399M (+33% YoY); full year $1.43B.
GAAP net income $89M ($0.88 diluted EPS) vs loss year-ago; non-GAAP net income $125M ($1.24 EPS).
FY2023 INGREZZA sales guidance $1.67-1.77B (tardive dyskinesia only); GAAP R&D $550-580M, SG&A $850-870M.
PDUFA date Aug 20, 2023 for valbenazine in Huntington chorea; crinecerfont registrational studies enrollment complete.
Acquired Diurnal Group (~$55M) Nov 2022; entered Voyager partnership for GBA1 gene therapy Jan 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NEUROCRINE BIOSCIENCES INC reported financial results for the fourth quarter and fiscal year ended December 31, 2022.

Period: the fourth quarter and fiscal year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 6, 2023, Neurocrine Biosciences, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2022.

View on SEC.gov

38 earnings releases filed in the last 30 days. Browse all earnings releases →

NEUROCRINE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000914475-23-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.